A novel cytotoxic anti-B7-H3 affibody with therapeutic potential in acute myeloid leukemia.

ABSTRACT:

Introduction

Acute Myeloid Leukemia (AML) is a group of very aggressive hematological malignancies, with dismal long-term survival rates and little therapeutic recourse presently. The transmembrane ligand B7-H3 is a known therapeutic target, biomarker of response and correlated with an unfavorable prognosis in several malignancies, including AML, due to acquired resistance to immune checkpoint-targeting therapies. Therefore, developing therapeutic strategies with improved efficacy to overcome this obstacle constitutes an unmet need. Our study entails the design, production and in vitro testing of a novel recombinant Affibody with high affinity for B7-H3 coupled with the cytotoxic peptide Magainin-2, known for its membranolytic properties and potent antimicrobial and antitumo

SUBMITTER: Vasilescu AM 

PROVIDER: S-EPMC12464454 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature